Beam Therapeutics Inc. reports results for the quarter ended September 30 - Earnings Summary

What happened

Beam Therapeutics reported a quarterly adjusted loss of $1.28 per share, wider than the $1.16 loss fifteen analysts expected. Revenue fell 96.8% to $307.00 thousand, far below the $8.75 million analysts expected, and the company posted a quarterly loss of $134.41 million.

Confirmed

Global impact / market context

The huge revenue miss and larger-than-expected loss show Beam earned far less than expected while spending heavily on research. For a biotechnology company, that gap can mean more reliance on cash reserves or raising new money, which may dilute existing shareholders.

Analyst inference

Most analysts rate the shares a buy, with a median price target of $44.00 versus the last close of $25.87, above the current price. That suggests analysts see room for recovery even as the company reports large losses.

Analyst inference

What to watch

1. Beam's revenue fell 96.8% to $307.00 thousand from a year earlier, well short of the $8.75 million analysts expected, so watch whether sales recover in the next quarter. Confirmed
2. Watch the company's cash balance and any plans to raise money, since a $134.41 million quarterly loss can shrink the cash available to fund research. Analyst inference
3. Track whether analysts revise their earnings estimates, because the average estimate already fell about 1.4% over three months with no revisions in the last 30 days. Proposed

Evidence

• Original source link unavailable